期刊
PATHOLOGY RESEARCH AND PRACTICE
卷 241, 期 -, 页码 -出版社
ELSEVIER GMBH
DOI: 10.1016/j.prp.2022.154232
关键词
Melanoma; Long non-coding RNAs; Biomarker; Diagnosis; Therapy
类别
Malignant melanoma is a rare but deadly skin malignancy that can invade other organs and metastasize. Surgery is a common treatment choice for melanoma patients. Non-coding RNAs, particularly long non-coding RNAs (lncRNAs), have been extensively studied in melanoma and may serve as potential markers for diagnosis, prognosis, and treatment.
Although extremely rare, malignant melanoma is the deadliest type of skin malignancy with the inherent capability to invade other organs and metastasize to distant tissues. In 2021, it was estimated that approximately 106,110 patients may have received the diagnosis of melanoma, with a mortality rate of 7180. Surgery remains the common choice for treatment in patients with melanoma. Despite many advances in the treatment of melanoma, some patients, such as those who have received cytotoxic chemotherapeutic and immunotherapic agents, a significant number of patients may show inadequate treatment response following initiating these treatments. Non-coding RNAs, including lncRNAs, have become recently popular and attracted the attention of many researchers to make new insights into the pathogenesis of many diseases, particularly malignancies. LncRNAs have been thoroughly investigated in multiple cancers such as melanoma and have been shown to play a major role in regulating various physiological and pathological cellular processes. Considering their core regulatory function, these non-coding RNAs may be appropriate candidates for melanoma patients' diagnosis, prognosis, and treatment. In this review, we will cover all the current literature available for lncRNAs in melanoma and will discuss their potential benefits as diagnostic and/or prognostic markers or potent therapeutic targets in the treatment of melanoma patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据